A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 44, 2010, Pages 19020-19025

  Neufeld Cohen, Adi ^a   Tsoory, Michael M ^a   Evans, Andrew K ^b   Getselter, Dmitriy ^a   Gil, Shosh ^a   Lowry, Christopher A ^b   Vale, Wylie W ^c   Chen, Alon ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITY OF COLORADO   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Amygdala; Anxiety like behaviors; Corticotropin releasing factor receptor type 2; Corticotropinreleasing factor; Serotonergic system

Indexed keywords

SEROTONIN; UROCORTIN;

ACUTE STRESS; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; BEHAVIOR; CELL STRESS; CELLULAR STRESS RESPONSE; CONFERENCE PAPER; GENE; GENE EXPRESSION; GENE FUNCTION; KNOCKOUT MOUSE; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL;

MUS;

EID: 78650431997     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1013761107     Document Type: Article

References (62)

1. de Kloet ER, Joëls M, Holsboer F (2005) Stress and the brain: From adaptation to disease. Nat Rev Neurosci 6:463-475.
2. McEwen BS (2007) Physiology and neurobiology of stress and adaptation: Central role of the brain. Physiol Rev 87:873-904.
3. Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213:1394-1397.
4. Bale TL, Vale WW (2004) CRF and CRF receptors: Role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44:525-557.
5. Müller MB, et al. (2003) Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6:1100-1107.
6. Vaughan J, et al. (1995) Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378:287-292.
7. Hsu SY, Hsueh AJ (2001) Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med 7:605-611.
8. Lewis K, et al. (2001) Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 98:7570-7575.
9. Reyes TM, et al. (2001) Urocortin II: A member of the corticotropin-releasing factor(CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 98:2843-2848.
10. Fekete EM, Zorrilla EP (2007) Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: Ancient CRF paralogs. Front Neuroendocrinol 28:1-27.
11. Kuperman Y, Chen A (2008) Urocortins: Emerging metabolic and energy homeostasis perspectives. Trends Endocrinol Metab 19:122-129.
12. Joëls M, Baram TZ (2009) The neuro-symphony of stress. Nat Rev Neurosci 10:459-466.
13. Chalmers DT, Lovenberg TW, De Souza EB (1995) Localization of novel corticotropinreleasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: Comparison with CRF1 receptor mRNA expression. J Neurosci 15:6340-6350.
14. Van Pett K, et al. (2000) Distribution of mRNAs encoding CRF receptors in brain andpituitary of rat and mouse. J Comp Neurol 428:191-212.
15. Hauger RL, Risbrough V, Brauns O, Dautzenberg FM (2006) Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: New molecular targets. CNS Neurol Disord Drug Targets 5:453-479.
16. Smith GW, et al. (1998) Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093-1102.
17. Timpl P, et al. (1998) Impaired stress response and reduced anxiety in mice lackinga functional corticotropin-releasing hormone receptor 1. Nat Genet 19:162-166.
18. Bale TL, et al. (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 24:410-414.
19. Coste SC, et al. (2000) Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet 24:403-409.
20. Risbrough VB, Hauger RL, Pelleymounter MA, Geyer MA (2003) Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl) 170:178-187.
21. Pelleymounter MA, Joppa M, Ling N, Foster AC (2002) Pharmacological evidence supporting a role for central corticotropin-releasing factor(2) receptors in behavioral, but not endocrine, response to environmental stress. J Pharmacol Exp Ther 302:145-152.
22. Pelleymounter MA, Joppa M, Ling N, Foster AC (2004) Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25:659-666.
23. Valdez GR, et al. (2002) Human urocortin II: Mild locomotor suppressive and delayedanxiolytic-like effects of a novel corticotropin-releasing factor related peptide. Brain Res 943:142-150.
24. Valdez GR, Sabino V, Koob GF (2004) Increased anxiety-like behavior and ethanol selfadministration in dependent rats: Reversal via corticotropin- releasing factor-2 receptoractivation. Alcohol Clin Exp Res 28:865-872.
25. Valdez GR, Zorrilla EP, Rivier J, Vale WW, Koob GF (2003) Locomotor suppressive andanxiolytic-like effects of urocortin 3, a highly selective type 2 corticotropin-releasingfactor agonist. Brain Res 980:206-212.
26. Venihaki M, et al. (2004) Urocortin III, a brain neuropeptide of the corticotropinreleasing hormone family: Modulation by stress and attenuation of some anxiety-like behaviours. J Neuroendocrinol 16:411-422.
27. Chu CP, et al. (2004) Central stresscopin modulates cardiovascular function throughthe adrenal medulla in conscious rats. Regul Pept 119:53-59.
28. de Groote L, Peñalva RG, Flachskamm C, Reul JM, Linthorst AC (2005) Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists. J Neurochem 94:45-56.
29. Lowry CA, Johnson PL, Hay-Schmidt A, Mikkelsen J, Shekhar A (2005) Modulation of anxiety circuits by serotonergic systems. Stress 8:233-246.
30. Servatius RJ, et al. (2005) A stress-induced anxious state in male rats: Corticotropinreleasing hormone induces persistent changes in associative learning and startle reactivity. Biol Psychiatry 57:865-872.
31. Henry B, Vale W, Markou A (2006) The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci 26:9142-9152.
32. Hale MW, et al. (2008) Exposure to an open-field arena increases c-Fos expression in a subpopulation of neurons in the dorsal raphe nucleus, including neurons projecting tothe basolateral amygdaloid complex. Neuroscience 157:733-748.
33. Pêgo JM, et al. (2008) Dissociation of the morphological correlates of stress-induced anxiety and fear. Eur J Neurosci 27:1503-1516.
34. Duvarci S, Bauer EP, Paré D (2009) The bed nucleus of the stria terminalis mediatesinter-individual variations in anxiety and fear. J Neurosci 29:10357-10361.
35. Mitra R, Ferguson D, Sapolsky RM (2009) Mineralocorticoid receptor overexpression in basolateral amygdala reduces corticosterone secretion and anxiety. Biol Psychiatry 66:686-690.
36. Tsoory MM, et al. (2008) Amygdala modulation of memory-related processes in the hippocampus: Potential relevance to PTSD. Prog Brain Res 167:35-51.
37. Rodríguez Manzanares PA, Isoardi NA, Carrer HF, Molina VA (2005) Previous stress facilitates fear memory, attenuates GABAergic inhibition, and increases synaptic plasticity in the rat basolateral amygdala. J Neurosci 25:8725-8734.
38. Sekiguchi M, et al. (2009) A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice. Brain 132:124-135.
39. Amat J, et al. (2004) Microinjection of urocortin 2 into the dorsal raphe nucleus activates serotonergic neurons and increases extracellular serotonin in the basolateral amygdala. Neuroscience 129:509-519.
40. LeDoux J (2007) The amygdala. Curr Biol 17:R868-R874.
41. Davis M, Whalen PJ (2001) The amygdala: Vigilance and emotion. Mol Psychiatry 6:13-34.
42. Holmes A (2008) Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease. Neurosci Biobehav Rev 32:1293-1314.
43. Nemeroff CB, Owens MJ (2009) The role of serotonin in the pathophysiology of depression: As important as ever. Clin Chem 55:1578-1579.
44. Dinan TG (1996) Serotonin and the regulation of hypothalamic-pituitary- adrenal axisfunction. Life Sci 58:1683-1694.
45. Lowry CA (2002) Functional subsets of serotonergic neurones: Implications for control of the hypothalamic-pituitary-adrenal axis. J Neuroendocrinol 14:911-923.
46. Carrasco GA, Van de Kar LD (2003) Neuroendocrine pharmacology of stress. Eur J Pharmacol 463:235-272.
47. Hammack SE, et al. (2003) Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress. J Neurosci 23:1019-1025.
48. Pernar L, Curtis AL, Vale WW, Rivier JE, Valentino RJ (2004) Selective activation of corticotropin-releasing factor-2 receptors on neurochemically identified neurons in therat dorsal raphe nucleus reveals dual actions. J Neurosci 24:1305-1311.
49. Maier SF, Watkins LR (2005) Stressor controllability and learned helplessness: The roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci Biobehav Rev 29:829-841.
50. Staub DR, Evans AK, Lowry CA (2006) Evidence supporting a role for corticotropinreleasing factor type 2 (CRF2) receptors in the regulation of subpopulations of serotonergicneurons. Brain Res 1070:77-89.
51. Rainnie DG (1999) Serotonergic modulation of neurotransmission in the rat basolateral amygdala. J Neurophysiol 82:69-85.
52. Evans AK, et al. (2008) Evidence for serotonin synthesis-dependent regulation of invitro neuronal firing rates in the midbrain raphe complex. Eur J Pharmacol 590:136-149.
53. Hale MW, Stamper CE, Staub DR, Lowry CA (2010) Urocortin 2 increases c-Fos expression in serotonergic neurons projecting to the ventricular/ periventricular system. Exp Neurol 224:271-281.
54. Magalhaes AC, et al. (2010) CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling. Nat Neurosci 13:622-629.
55. Neufeld-Cohen A, et al. (2010) Urocortin-1 and -2 double-deficient mice show robustanxiolytic phenotype and modified serotonergic activity in anxiety circuits. Mol Psychiatry 15:426-441.
56. Vetter DE, et al. (2002) Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nat Genet 31:363-369.
57. Wang X, et al. (2002) Urocortin-deficient mice display normal stress-induced anxiety behavior and autonomic control but an impaired acoustic startle response. Mol Cell Biol22:6605-6610.
58. Chen A, et al. (2006) Urocortin 2-deficient mice exhibit gender-specific alterations in circadian hypothalamus-pituitary-adrenal axis and depressive-like behavior. J Neurosci 26:5500-5510.
59. Deussing JM, et al. (2010) Urocortin 3 modulates social discrimination abilities via corticotropin-releasing hormone receptor type 2. J Neurosci 30:9103-9116.
60. Li C, Vaughan J, Sawchenko PE, Vale WW (2002) Urocortin III-immunoreactive projections in rat brain: Partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J Neurosci 22:991-1001.
61. Regev L, et al. (2010) Prolonged and site-specific over-expression of corticotropinreleasing factor reveals differential roles for extended amygdala nuclei in emotional regulation. Mol Psychiatry, in press.
62. Sztainberg Y, Kuperman Y, Tsoory M, Lebow M, Chen A (2010) The anxiolytic effect ofenvironmental enrichment is mediated via amygdalar CRF receptor type 1. Mol Psychiatry 15:905-917